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No licensed human vaccines are currently available against any parasitic disease 
including leishmaniasis. Several antileishmanial vaccine formulations have been tested 
in various animal models, including genetically modified live-attenuated parasite vac-
cines. Experimental infection studies have shown that Leishmania parasites utilize a 
broad range of strategies to undermine effector properties of host phagocytic cells, i.e., 
dendritic cells (DCs) and macrophages (MΦ). Furthermore, Leishmania parasites have 
evolved strategies to actively inhibit TH1 polarizing functions of DCs and to condition the 
infected MΦ toward anti-inflammatory/alternative/M2 phenotype. The altered phenotype 
of phagocytic cells is characterized by decreased production of antimicrobial reactive 
oxygen, nitrogen molecules, and pro-inflammatory cytokines, such as IFN-γ, IL-12, and 
TNF-α. These early events limit the activation of TH1-effector cells and set the stage for 
pathogenesis. Furthermore, this early control of innate immunity by the virulent parasites 
results in substantial alteration in the adaptive immunity characterized by reduced pro-
liferation of CD4+ and CD8+ T cells and TH2-biased immunity that results in production 
of anti-inflammatory cytokines, such as TGF-β, and IL-10. More recent studies have 
also documented the induction of coinhibitory ligands, such as CTLA-4, PD-L1, CD200, 
and Tim-3, that induce exhaustion and/or non-proliferation in antigen-experienced 
T cells. Most of these studies focus on viral infections in chronic phase, thus limiting 
the direct application of these results to parasitic infections and much less to parasitic 
vaccines. However, these studies suggest that vaccine-induced protective immunity can 
be modulated using strategies that enhance the costimulation that might reduce the 
threshold necessary for T cell activation and conversely by strategies that reduce or 
block inhibitory molecules, such as PD-L1 and CD200. In this review, we will focus on 
the polarization of antigen-presenting cells and subsequent role of costimulatory and 
coinhibitory molecules in mediating vaccine-induced immunity using live-attenuated 
Leishmania parasites as specific examples.
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iNTRODUCTiON
Visceral leishmaniasis (VL) has an annual incidence of 0.2–0.4 
million cases globally and results in about 60,000 deaths (1). It 
has been reported that 0.7–1.2 million cases of cutaneous leish-
maniasis (CL) occur around the globe (2). The disease currently 
affects 12 million people with 350 million people at risk of infec-
tion. The majority of patients with CL or VL develop a long-term 
protective immunity after cure from infection, which suggests 
that development of an effective vaccine against leishmaniasis is 
possible (3, 4). High frequency of asymptomatic infections, toxic-
ity of currently available drugs, and increasing parasite resistance 
underline the need for an effective prophylactic vaccine against 
leishmaniasis (5).
Extensive studies in murine models that acquire resistance 
to Leishmania major infection have resulted in a broader under-
stating of the mediators of protection, primarily a TH1-biased 
response (6). However, the principal determinants for inducing 
a strong TH1-type response following infection with virulent 
Leishmania parasites including expression of MHC-I/II, CD40, 
CD80/CD86, and cytokines, such as IL-12, by the antigen-
presenting cells (APCs) [dendritic cells (DCs) and macrophages 
(MΦ)] are targets for alteration by the parasites (7, 8). Leishmania 
parasites can survive in a wide range of cell types. The parasites 
are phagocytosed by neutrophils first and are taken up by the MΦ 
and DCs without causing an overt immunological reaction (6). 
The multifarious interactions between Leishmania and the host 
APCs have profound effects on the final outcome of the interac-
tion, either host resistance or susceptibility. MΦ are not only the 
primary host cell for Leishmania that permit parasite proliferation 
but also the major effector cells in eliminating the infection. The 
effective clearance of parasites by MΦ depends on the activation of 
an appropriate immune response usually initiated by the DCs (8).
RePROGRAMiNG OF MACROPHAGe/DC 
DiFFeReNTiATiON
Leishmania donovani resides predominantly in host MΦ where 
it enters by phagocytosis and establishes itself within parasito-
phorous vacuoles (9). Macrophage responses to parasites lead to 
discrete, stereotyped phenotypes, which are usually a combina-
tion of inflammatory and anti-inflammatory functions (8). This 
plasticity in macrophage function has been defined either as 
classically activated (M1 phenotype) representing leishmanicidal 
activity or an alternatively activated state (M2 phenotype) that 
confers susceptibility to infection (10).
Classically activated macrophages (CAM) are primed by TH1 
(or pro-inflammatory) cytokines and triggered by microbial 
products to produce antimicrobial molecules, such as reactive 
oxygen species (ROS) and nitric oxide (NO), through the action of 
inducible nitric oxide synthase (iNOS) and subsequently acquire 
a heightened effector function (11–13). CAM activation is also 
characterized by the induction of an array of pro-inflammatory 
cytokines, such as tumor necrosis factor [TNFα, IL-1β, and inter-
leukin (IL)-12], which amplify TH1 immune responses (14–16). 
Specifically, IL-12 is a pivotal cytokine required for CD4+ TH1 
development and production of IFN-γ (17). Since CAMs acquire 
properties necessary for the destruction of invading pathogens 
and priming the innate immune response, Leishmania parasites 
have evolved mechanisms to subvert microbicidal functions of 
the CAMs through depletion of antimicrobial molecules, such 
as ROS and NO (18–20), thereby reprograming the infected MΦ 
to an alternative activation state (21). Alternative macrophage 
activation is mainly induced by TH2 cytokines (22, 23) that 
antagonize the microbicidal properties of CAMs (8).
The enhanced TH2 response during virulent Leishmania infec-
tion leads to enhanced arginase activities in the MΦ, a prototypic 
alternative activation marker in mouse MΦ that allows parasite 
survival (22–24). Of the TH2 cytokines, IL-10 has emerged as 
the principal cytokine responsible for disease pathogenesis (25). 
IL-10 induced during Leishmania infection inhibits microbicidal 
activity of MΦ by attenuating the generation of NO and pro-
inflammatory cytokines (26). Therefore, reprograming of the MΦ 
enables Leishmania parasites to evade the antimicrobial innate 
immune response and to proliferate within the phagolysosome 
of the macrophage.
The critical balance between host-protective TH1 (or 
pro-inflammatory) versus disease-promoting TH2 (or 
 anti-inflammatory) effector responses determines the outcome 
of infection in leishmaniasis. This outcome is dictated by the 
relative levels of IL-12 and IL-10 produced by the classical/M1 
and alternative/M2 MΦ, respectively (8, 16, 21). Previous studies 
have also shown that the MΦ are able to regulate immunologic 
outcomes on their own via directing the T cell response (27, 28). 
For example, infection of MΦ with virulent Leishmania induces 
a parasite-favoring TH2 response instead of a host-protective TH1 
response (29). Interestingly, studies have shown that classical/
pro-inflammatory/M1 MΦ have a direct role in the induction of 
TH1-polarized response (16, 27, 28, 30). Such M1 macrophage-
induced T cell polarization was further linked with an induction 
of protection in several vaccine studies including recombinant 
BCG, attenuated West Nile virus (WNV), and live-attenuated 
measles virus (31–33). These recent studies demonstrated that 
the vaccine antigens, indeed, reprogram the MΦ to induce a 
pro-inflammatory response and result in improved protective 
immunity. Likewise, our studies with genetically modified live-
attenuated L. donovani parasites revealed that these attenuated 
parasites induce classical activation of MΦ that direct host-
protective TH1 response in mice (21). A recent study has also 
reported that M2 polarization of monocytes–macrophages is a 
hallmark of post kala-azar dermal leishmaniasis that sustains 
chronic lesions (10). Additionally, repolarization of the mono-
cytes to M1 type by antileishmanial drugs as stated above suggests 
that switching from M2 to M1 phenotype might also be important 
in a therapeutic setting similar to what our studies indicated with 
prophylactic vaccination (21).
Although an effective clearance of parasites involves antimi-
crobial activity of the MΦ, the main host cell for Leishmania 
parasites, it also requires the activation of an appropriate immune 
response that is initiated by DCs (7, 8). Since MΦ are not the 
major producers of IL-12, potentiation of adaptive immune 
response depends primarily on the DC-derived IL-12 (34). In 
addition, parasite-infected MΦ are incompetent in priming 
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naive CD4+ T cells as well as stimulating antigen (Ag)-specific 
CD4+ T cells (35). Thus, DCs play a crucial role in coordinating 
immune responses in leishmaniasis by providing the IL-12 neces-
sary for the induction of protective TH1 response (36, 37). In both 
L. major and L. donovani mouse studies, the central role of DCs 
in determining the TH1/TH2 balance as well as the outcome of 
disease is demonstrated (36, 38). Specifically, L. donovani infec-
tion is shown to cause DCs to produce IL-12 that leads to NK 
cell activation (36). In the spleen, interaction between DCs and 
T cells occurs in the periarteriolar lymphoid sheath (PALS) into 
which DC and T cells migrate from the marginal zone (MZ) along 
chemokine gradients, especially CCL19/21, and this interaction 
between DCs and the T cells is necessary to produce protective 
immunity against L. donovani (39). Leon et al. also reported that 
monocyte–DCs formed at the infection site control the induction 
of protective TH1 responses against Leishmania (37). Nevertheless, 
infection with virulent Leishmania parasites is shown to prevent 
development of protective TH1 immunity by dysregulating DC 
function (7, 40). Additionally, Moll et al. reported that L. major 
parasites inhibit TH1 polarizing functions of epidermal-derived 
DCs (Langerhans cells) by upregulating IL-4 receptor expression 
along with concomitant downregulation of IL-12p40 production 
(41). Of interest, virulent Leishmania interferes with intracellular 
signaling in DCs, which affects their antigen-presenting func-
tions, and hence, their ability to induce optimal cell-mediated 
immunity against the parasite (7, 42). DCs infected with intracel-
lular pathogens, such as Leishmania, have been shown to elicit an 
MHC class-I-dependent CD8+ T-cell response, a process referred 
to as cross-presentation (43). Further studies have demonstrated 
the role of Leishmania-induced cleavage of proteins, such as 
SNAREs, that mediate the fusion of phagosomes with lysosomes, 
a key process in the antigen processing and presentation to the 
T cells (44, 45).
The role of DCs in priming a protective TH1 response is also 
illustrated by DC vaccination studies where exogenous adminis-
tration of antigen-loaded DCs showed promising results in the 
treatment of different forms of leishmaniasis (46, 47). Curiously, 
adoptive transfer of DCs pulsed ex vivo with soluble L. donovani 
Ags (SLDA) to naive mice induced the Ag-specific production 
of IFN-γ and increased the percentage of activation markers on 
spleen lymphocytes. Moreover, SLDA-pulsed DCs engineered by 
retroviral gene transfer techniques to secrete high levels of bio-
logically active murine-IL-12 augmented this immune response, 
further indicating the central role of DC secreted IL-12 in potenti-
ating a protective response (48). Additionally, Schnitzer et al. have 
reported that DCs pulsed ex vivo with L. major antigen-induced 
protection in otherwise susceptible mice against subsequent 
challenges with the parasites (49). While it is well documented 
that antigen-loaded DC-based vaccines can induce protective 
immunity against Leishmania pathogenesis (50), live-attenuated 
parasites might be more practical in inducing protective immu-
nity by modulating the DC function as illustrated by studies per-
formed using DC-based vaccines. Taken together, these studies 
indicate that for an antileishmanial vaccine to induce protective 
immunity, TH1 favoring conditions in the DCs is a necessary 
requirement and live-attenuated parasite vaccines might be able 
to set in those conditions.
DeTeRMiNANTS OF T CeLL iMMUNiTY
An effective long-term protection requires activation of adap-
tive immunity mediated by T lymphocytes. APCs, primarily 
DCs, present processed antigens in combination with major 
histocompatibility complex to naive T cells displaying the corre-
sponding T cell receptor. However, this presentation also requires 
additional signals arising from positive and negative coreceptors, 
i.e., costimulatory and coinhibitory molecules. The response of 
the T cell thus activated requires an amalgam of signals from 
the immunological synapse, and T cell activation can only occur 
when the stimulatory/inhibitory signals are able to overcome a 
certain threshold (51). Of the stimulatory signals, CD28 is the 
best-studied costimulatory molecule. Involvement of CD28 in 
the immunological synapse decreases the amount of antigen 
necessary to elicit T cell activation. Importantly, inflammatory 
signals regulate expression of CD28-binding partners, such as 
B7-1 (CD80) and B7-2 (CD86). Previous studies have identified 
suppression of costimulatory signals in DCs infected with viru-
lent Leishmania parasites that results in poor IL-12 production 
and CD4+ T cell priming (36, 52–54). A TH2-polarized response 
was observed in CD40−/− mice as indicated by excessive IL-4 and 
low IFN-γ. A direct role for CD40:CD40L ligation was shown 
not only in production of IL-12p70 but also in activation of T 
cells by the DCs (55, 56). Deficient expression of costimulatory 
CD80 was observed in L. donovani-infected MΦ (57). Similarly, 
CD86 has been shown to orchestrate either a TH1 or TH2 type 
response depending on the relative contribution of CD80 (58). 
More recently, several immune inhibitory mechanisms have been 
explored, which control exacerbated immune response of the host 
to prevent self-damage from unchecked inflammation (59). These 
mechanisms not only control the effector function of immune 
cells but also reprogram them for their alternate functions, 
such as humoral immunity and tissue remodeling, to maintain 
homeostasis between an immune response and immune toler-
ance. The interplay between signals arising from costimulatory 
molecules and coinhibitory molecules has been identified as a 
critical determinant in T cell activation. It has been hypothesized 
that costimulatory signals may act like a “rheostat” to modulate 
T cell activation in that costimulatory molecules reduce the 
TCR signaling threshold necessary for T cell activation, whereas 
inhibitory molecules restrict T cell activation (60).
Although there is considerable debate over the requirements 
for maintaining protection against reinfection in Leishmania, 
studies have shown that antigen-specific memory T cells are a 
principal component of protective immunity to intracellular 
pathogens, such as L. major (61–65). The memory T cells are 
distinguished by their ability (i) to survive long term in secondary 
lymphoid tissues and (ii) to undergo rapid and robust prolifera-
tion upon reinfection and acquisition of effector function. Yet, our 
understanding of T cell differentiation and memory formation is 
mainly derived from models of acute viral and bacterial infections, 
such as Lymphocytic Choriomeningitis Virus, Vaccinia virus, and 
Listeria monocytogenes. Persistent infections, such as Leishmania, 
may differ in significant ways from these models in the T cell 
response dynamics. Several dysfunctions including severe limita-
tion in T cell expansion, delay in peak T cell expansion, anergy, 
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and expression of exhaustion markers in chronic infections have 
been reported (66–69).
In an acute infection, the T cell response typically follows 
three phases: expansion, contraction, and memory. During the 
first phase, upon presentation of antigens by DCs, naive T cells 
divide and differentiate into effector cells that acquire the ability to 
produce the pro-inflammatory cytokines IFN-γ and TNF, as well as 
cytotoxic proteins such as granzymes and perforin. This cascade of 
events by which T lymphocytes undergo differentiation and clonal 
expansion is regulated by signaling via antigens, costimulation, 
and cytokine receptors that induce the expression of transcription 
factors that dictate the fate of the T cells to acquire either an effec-
tor function or memory precursors (70). In case of CD8+ T cells, 
the cell fates are controlled by a coordinated set of changes in the 
expression of the transcription factors Id2, T-bet, and Blimp-1, 
which promote terminally differentiated effector cells, and Foxo1, 
TCF-1, Eomes and Bcl-6, which promote development of memory 
precursors (71–73). Earlier studies in L. donovani demonstrated the 
role of CD8+ T cells in the resolution of infection (74). In virulent 
L. donovani infection of mice, induction of exhausted CD8+ T cells 
has been demonstrated (66). More recent studies have shown a role 
for the transcription factor IRF-5 in regulating the antigen-specific 
CD8+ T cells responses during murine L. donovani infection (75). 
Inflammatory response generated by IRF-5 is shown to induce the 
expression of HIF-α in DCs and to limit CD8+ T cell expansion (75). 
Development of CD4+ T cells responses following either a chronic 
infection in comparison are less well studied (76). However, the 
dynamics of T cell effector/memory responses in a prophylactic 
vaccine setting are less well understood. It may be argued that in 
contrast to virulent parasites, prophylactic vaccines are composed 
of attenuated parasites due to their inherent immunomodulatory 
attributes may be able to induce conditions optimal for the immune 
system to generate memory cells that confer protection against 
subsequent infection (Figure 1). On the other hand, recombinant 
antigens may, and often, require adjuvants to enhance T cell 
responses. More systematic studies with prophylactic candidate 
vaccines are necessary to reveal the necessary conditions that must 
precede a strong protective response.
COiNHiBiTORY MOLeCULeS iN 
PATHOGeNeSiS AND vACCiNe iMMUNiTY
In a chronic infection, it is essential that the host immune 
response be appropriately controlled to respond to and remove 
pathogens while avoiding excessive production of inflammatory 
cytokines and chemical mediators, such as ROS. The immune 
inhibitory signals, therefore, can dampen the effects of excessive 
immune reactions, which can lead to increased tissue damage and 
morbidity and mortality. In the following sections, we describe 
the role of various coinhibitory molecules and discuss their 
potential roles in inducing protective immunity with implication 
to live-attenuated vaccines.
CTLA-4
B7 molecules expressed by DCs and MΦ are upregulated fol-
lowing activation. These B7 molecules B7-1 (CD80) and B7-2 
(CD86) have dual specificity for receptors CD28 and CTLA-4 on 
T cells (77). CTLA-4 is an inhibitory coreceptor that is induced 
rapidly by activated T cells (78). Because of its higher affinity to 
CD80/86 than CD28, CTLA-4 often outcompetes and excludes 
CD28 from the immunological synapse, thereby causing suppres-
sion of T cell activation. In symptomatic VL, both the splenic 
aspirates and PBMCs from L. donovani-infected humans showed 
higher level of CTLA-4 expression (69). Higher CTLA-4 expres-
sion was also observed in PKDL lesions suggesting an association 
with persistence of parasites (79). Higher frequencies of CTLA-4+ 
CD4+ T cells have been identified in HIV-Leishmania coinfections 
that are associated with a poor immunological profile that might 
explain the persistence and relapse of the Leishmania infection 
(80). However, treatment with anti-CTLA-4 has shown mixed 
results. Blockade of CTLA-4 resulted in enhanced granuloma 
maturation indicating parasite-killing activity in the liver; how-
ever, in splenic aspirate cultures of human VL samples, CTLA-4 
blockade did not show an increase in IFN-γ production (69, 81). 
The role of CTLA-4 in T cell activation has not been studied in a 
Leishmania vaccine setting. Reports have shown that preventing 
CTLA-4 interactions can improve T cell activation in other vac-
cine models. For example, in vivo blockade of CTLA-4 enhances 
antigen-specific CD4+ T cell responses after peptide immuniza-
tion in complete Freund’s adjuvant for cryptococcal infection 
(82). Transient CTLA-4 blockade increased the number of 
memory CD8+ T cells during low-dose Listeria infection in mice, 
and CTLA-4 blockade enhanced the response of memory CD8+ 
T cells (83). The mechanism by which blockade of CTLA-4 might 
exert its functions is not completely understood. It has been pro-
posed that blocking CTLA-4 might dampen the IL-10-mediated 
suppressive effects since CTLA-4 is very highly expressed on Treg 
cells (84). CTLA-4 plays an important role in the homeostasis 
and function of a population of suppressive activities of Treg cells 
(85). A direct role for CTLA-4 in T cell activation is suggested by 
studies that showed removal of B7 molecules from the surface 
of APCs by blocking CTLA-4 and, thus, increase the signal 
threshold necessary for T cell activation (86). Taken together, 
these studies suggest that CTLA-4 might be a potential target for 
modulation by prophylactic vaccines because of its effects first on 
T cell activation by its effects on B7 molecules and second by its 
ability to affect Treg cells.
PROGRAMeD DeATH-1
Programed death-1 (PD-1) is an inhibitory receptor that is induc-
ibly expressed on stimulated CD4+ T cells, CD8+ T cells, B cells, 
and monocytes (66, 68, 87). PD-1 modulates T cell receptors and 
CD28 signaling through recruitment of the phosphatase SHP2. 
PD-1 binds to B7 family ligands, PD-L1 (B7-H1/CD274) and 
PD-L2 (B7-DC/CD273) (88). PD-L1 expression occurs on a 
wide variety of cells, whereas PD-L2 expression is restricted to 
APCs (DCs, monocytes, and some B cell subsets). Expression of 
both PD-1 ligands is modulated by cytokines, such as IL-2, IL-7, 
IL-15, IL-21, and IFN-γ (87, 89). Expression of PD-1 is induced 
by antigen receptor ligation and is dampened after resolution 
of infection in the absence of TCR signaling (90). However, 
sustained PD-1 expression is reported in several chronic disease 
FiGURe 1 | A schematic diagram describing the differential modulation of antigen-presenting cells in the early innate response and role of 
coinhibitory molecules in adaptive immunity in Leishmania pathogenesis is shown. (A) Virulent Leishmania donovani parasites are known to suppress 
antigen-presenting activity of DCs and macrophages. This is shown to be accompanied by reduction in the inflammatory cytokines as compared to infection with 
live-attenuated L. donovani parasites. These differences in the early interaction with the host APCs by the parasites determine the outcome, i.e., host susceptibility 
in case of virulent parasites or host resistance in case of attenuated parasites. (B) Previous studies have shown the role of coinhibitory molecules, such as CTLA-4, 
PD-L1, and CD200, in facilitating the parasite survival by inducing a restrained pro-inflammatory (TH1) environment. The role of Tim-3 in Leishmania pathogenesis 
remains to be explored. The role of coinhibitory molecules in shaping the T cell immunity suggests that attenuated parasites might downregulate these pathways 
compared to virulent parasites in order to induce protective immunity. Blockade of the coinhibitory signals during priming by use of adjuvants might show potential 
improvement in the vaccine-induced immunity.
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models, including leishmaniasis, malaria, and Chagas (91–95). 
Specific parasite molecules (LPG from Leishmania mexicana) 
have also been shown to induce PD-1 expression in CD8+ T cells 
and PD-L2 in MΦ (96). Sustained PD-1 expression is maintained 
primarily due to continuous TCR ligation, and PD-1 ligation 
dramatically shifts the dose-response curve, making T cells 
much less sensitive to T-cell receptor-generated signals (97). TCR 
signals promote demethylation of regulatory regions of the PD-l 
locus. Additionally, transcription factor T-bet binds upstream of 
the PD-1 gene and represses its transcription. Since T-bet expres-
sion is downregulated in persistent TCR stimulation, low T-bet 
expression enables PD-1 transcription (98). Elevated expression 
of T-bet and PD-1 in CD4+ T cells in the patients of tuberculosis 
was also reported (99). In addition, recent studies have also iden-
tified transcriptional factors, hypoxia-inducible factor (HIF)-1α 
and signal transducer and activation of transcription 3 (STAT-3), 
that act on the promoter of PD-L1 to regulate its expression. In 
addition, microRNAs, including miR-570, miR-513, miR-197, 
miR-34a, and miR-200, negatively regulate PD-L1 (100).
Sustained PD-1 expression is a hallmark of dysfunctional 
T cells and commonly found in chronic infections. Importantly, 
several studies have shown that interfering with the PD-1 path-
way rescues function in exhausted T cells including Leishmania 
and Plasmodium infections (66, 68, 87, 93, 101). Similar 
observations were also described in hepatitis C virus-infected 
patients that interfering with the PD-1/PD-L1 pathway during 
the early stage of immune responses can result in improved 
T cell responses (102). PD-L1 blockade during acute herpes 
simplex virus (HSV)-1 infection is shown to increase the mag-
nitude and polyfunctionality of the HSV-specific CD8+ effector 
responses (103).
An important role as a clinical intervention for the PD-1 
pathway in T cell exhaustion was first shown in LCMV infection 
in mice (104) and later demonstrated to occur in a diverse range of 
clinically relevant chronic human infections, such as HIV infection, 
hepatitis B and hepatitis C virus infections, and cancer (105–107). 
Several studies also tested combination of PD-1 and other ligands 
in blockade therapies (108, 109). Compared to clinical advances 
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in treating cancer, blockade of inhibitory receptors as a strategy to 
treat chronically infected patients has lagged behind.
In addition to the role of PD-L1/PD-1 in regulating T cell 
function, it has been proposed that PD-L1/PD-1 interaction 
through the regulation by IFN-γ might allow for recognition of 
minor epitopes that otherwise would not be selected. This is con-
sistent with the observation that PD-1 engagement preferentially 
inhibits low-avidity antigen receptors and thus allows expansion 
of immunodominant clones (89). In addition, in the absence of 
PD-L1/PD-1 interactions, APCs provide stronger stimulation to 
T cells. This is supported by experiments showing a significant 
enhancement of HIV-specific T cell responses by blocking PD-L1 
(110). As a result, blockade of the PD-1 pathway has more signifi-
cant effects in promoting T cell activation during conditions of 
suboptimal antigen presentation, such as with low antigen dose 
or with weak or low numbers of APCs (89).
Taken together, these studies suggest that PD-1 pathway 
blockade is an attractive strategy to improve prophylactic vac-
cination by allowing for better antigen selection and better T cell 
functional responses. Even though PD-1 pathway blockade is 
an attractive strategy to improve prophylactic vaccination, few 
studies have focused on the PD-1 pathway during early stages of T 
cell responses. Most importantly, PD-1 blockade has been studied 
in assessing CD8+ T cell responses, whereas the role of the PD-1 
pathway on CD4+ T cell differentiation, an important mediator of 
antileishmanial immunity, has been relatively neglected.
CD200R
CD200R is an inhibitory receptor expressed in the cells of lym-
phoid lineage, such as NK cells, CD4+, and CD8+ T cells, especially 
upon stimulation (59). Its ligand, CD200 (OX2), is a glycoprotein 
expressed on a broad number of cell types, including solid tumors 
and hematologic malignancies. Studies have also shown differen-
tial expression of CD200R on T cell subsets in mice and humans 
including effector and central memory T cells (111).
CD200R1 is an Ig superfamily transmembrane glycoprotein 
expressed on the surface of myeloid cells; it can also be induced in 
certain T-cell subsets (112, 113). CD200R1 interacts with CD200, 
which is also an Ig superfamily transmembrane glycoprotein, 
to downregulate myeloid cell functions. CD200 is expressed 
on the surface of a variety of cells including neurons, epithelial 
cells, endothelial cells, fibroblasts, lymphoid cells, and astrocytes 
(112, 114–116). The regulation of CD200R1 signaling can occur 
by posttranslational modifications mainly by phosphorylation 
of tyrosine residues in the CD200R1 cytoplasmic tail or by the 
inducible expression or the downregulation of either CD200R1 or 
CD200. Each of these mechanisms can be exploited by pathogens.
Unlike most immune inhibitory receptors, CD200R1 does 
not contain an immunoreceptor tyrosine-based inhibitory motif 
(ITIM). Stimulation by CD200 leads to the phosphorylation of 
these tyrosines by Src kinases, which recruit the adapter protein 
downstream of tyrosine kinase (Dok2) through its PTB domain 
(117). Dok2 serves as the major initiator of signaling through 
CD200R1, beginning with binding to Ras-GTPase-activating 
protein (RasGAP) and is required for CD200R1 function (117). 
This is in contrast to ITIM containing inhibitory receptors, 
which utilize SHPs and SHIP-1 as the major initiator proteins 
and Dok proteins as secondary modulators of downstream 
signaling (117, 118).
Compared to other inhibitory molecules, CD200 is less well 
studied in parasitic infections. Leishmania amazonensis, which 
causes severe disease in both humans and mice, induces CD200 
expression in bone marrow MΦ from wild-type mice (119). 
Induction of CD200 upon infection was essential for the parasite 
virulence and development of systemic Leishmaniasis. Addition 
of CD200-Fc restored the virulence of L. amazonensis in mice 
lacking CD200. Distinct differences in CD200 signaling have 
been identified with other Leishmania species. L. major, which 
causes only localized cutaneous lesions, does not induce CD200 
in MΦ. Interestingly, however, treatment with CD200-Fc of 
L.  major-infected mice caused the parasite to disseminate into 
a systemic infection similar to that of L. amazonensis (119). 
L. amazonensis has evolved to utilize CD200 expression as a 
mechanism for inhibiting both NO production and induction of 
iNOS during infection. Interestingly, L. amazonensis increased 
CD200 expression on MΦ. MΦ have generally been found to 
express CD200R1, which can then interact with non-myeloid 
cells expressing CD200. Interestingly, mice lacking CD200 
induced robust antiviral immunity including virus-specific CD4+ 
T cell responses (120). In two chronic infection models including 
Salmonella and Schistosoma, upregulated CD200R expression 
has been shown to result in poor multifunctional CD4+ T cell 
responses (112). Upregulated CD200R expression was associ-
ated with the development of TH2-type response. These results 
indicate that CD200 could be a candidate target for investigation 
as a regulator of T cell immunity in prophylactic antileishmanial 
vaccines since multifunctional CD4+ T cells have been shown 
to be correlated with protection in several Leishmania vaccine 
studies (Figure 1) (121, 122).
TiM-3
The Tim-3 protein is a member of the T cell immunoglobulin 
and mucin domain (Tim) family, which encompasses a group 
of type-I transmembrane proteins expressed by both innate and 
adaptive cell types within the immune system. All Tim proteins 
are expressed on the cell surface and have been shown to function 
as receptors for soluble or cell-associated ligands. Additionally, 
certain Tim proteins can be shed from the cell surface and be 
found in soluble forms, suggesting a role as cell-free ligands. To 
date, the IgV domain of Tim-3 has been shown to interact with 
phosphatidylserine (PS) displayed on the surface of apoptotic 
cells, the alarmin protein high mobility group box 1 (HMGB1), 
and Galectin-9, a widely expressed soluble protein with specific-
ity for carbohydrate chains containing β-galactoside sugars. Of 
the several ligands, the interaction between Tim-3 and Galectin-9 
has been shown to impact CD4+ T cell functions. Addition of 
Galectin-9 to cultured Tim-3 TH1-type CD4+ T (TH1) cells 
induced apoptosis and necrosis, while injection of Galectin-9 into 
mice blunted immune responses driven by antigen-specific TH1 
cells. These studies indicated that binding of Galectin-9 to Tim-3 
results in the suppression of T cell responses, which supports the 
notion that Tim-3 functions as an inhibitory receptor for T cells.
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A role for Tim-3 in regulating responses by CD4+ T cells has 
been suggested based on studies where addition of Galectin-9 
induced the death of Tim-3+ TH1 cells in  vitro. Other studies 
using autoimmune disease models suggest that ligation of Tim-3 
by Galectin-9 leads to suppression of TH1-dependent immune 
responses. Studies of microbial infections also sought to investi-
gate how Tim-3 and Galectin-9 influence CD4+ T cell responses. 
Tim-3 overexpression was observed on T cells that were senes-
cent and dysfunctional in HCV infection, and blockade of Tim-3 
rescued dysfunctional CD4+ and CD8+ T cells (123). In contrast, 
active tuberculosis patients exhibited increased numbers of 
Tim-3-expressing CD4+ and CD8+ T cells, which preferentially 
displayed polarized effector memory phenotypes. Tim-3+ CD4+ 
and CD8+ T cell subsets showed greater effector functions for 
producing Th1/Th22 cytokines and CTL effector molecules than 
those lacking Tim-3 expression, and Tim-3+ T cells controlled 
intracellular Mtb replication in MΦ (124). Overall, these findings 
suggest that Tim-3 can promote CD4+ T cell responses mounted 
against Mtb infection. This conclusion contrasts with other studies 
that showed Tim-3 expression correlated with T cell exhaustion. 
Taken together, these findings raise the possibility that Tim-3 
function is influenced by context and that Tim-3 may inhibit or 
promote CD4+ T cell responses depending upon the microbe 
involved and the characteristics of the immune response elicited 
by the infection. Elevated expression of Tim-3 expression on T 
cells from HIV-1-infected individuals correlated positively with 
HIV-1 viral load and CD38 expression and inversely with CD4+ 
T cell count. In progressive HIV-1 infection, Tim-3 expression 
was upregulated on HIV-1-specific CD8+ T cells (125). Blocking 
the Tim-3 signaling pathway restored proliferation and enhanced 
cytokine production in HIV-1-specific T cells (125). In addition, 
blocking of Tim-3 rescued macrophage and T cell function in 
HIV positive tuberculosis patients (126). Persistence of HCV 
was associated with lower frequencies of IL-21-producing CD4+ 
T cells, reduced proliferation, and increased expression of the 
inhibitory receptors Tim-3, PD-1, and CTLA-4 on HCV-specific 
CD8+ T cells. Progression to persistent infection was accompa-
nied by increased plasma levels of the Tim-3 ligand Galectin-9 
and expansion of Gal-9 expressing regulatory Treg cells (127). 
Thus, studies in a diverse pathogen models suggests a net nega-
tive impact of Tim-3 expression on T cell-dependent antiviral 
immune responses. However, studies in Mtb point out that the 
Tim-3 expression and T cell function may be pathogen-specific. 
Consistent with this, in murine malaria, expression of both Tim-3 
and Galectin-9 were associated with liver damage and acute lung 
injury (128, 129), suggesting a role in pathogenesis. It would be 
of interest to study if Tim-3 signaling has any role in prophylactic 
parasite vaccines.
CONCLUSiON
Chronic infections with intracellular parasites have been shown 
to induce several inhibitory molecules that subvert the develop-
ment of protective immunity in the host and favor the survival of 
the parasite by mainly preventing the development of functional 
T cell immunity. While the role of these coinhibitory signals in 
virulence is being explored, important questions regarding their 
roles in shaping the protective immunity in a prophylactic vac-
cine setting are being recognized. The role of inhibitor signals in 
not only regulating T cell functions but modifying the adaptive 
immunity suggests that these molecules could be potential tar-
gets for modulation by candidate vaccines. Importantly, studies 
using blockade of ligands, such as PD-L1 and CTLA-4, have 
revealed important insights as to the clinical importance of such 
interventions.
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